60 | CLONAL HEMATOPOIESIS IN DIFFUSE LARGE B‐CELL LYMPHOMA
Deborah Piffaretti(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Lodovico Terzi di Bergamo(Institute of Oncology Research), Greta Guarda(Università della Svizzera italiana), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Maria Cristina Pirosa(Institute of Oncology Research), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Júlia Almeida(Universidad de Salamanca), Hanif Javanmard Khameneh(Università della Svizzera italiana), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Simone Bocchetta(Institute of Oncology Research), Sämi Schär(Swiss Group For Clinical Cancer Research), Alessandro Zenobi, Anastasios Stathis(Princess Margaret Cancer Centre), Sara Monticelli, Matin Salehi(SIB Swiss Institute of Bioinformatics), Gabriela Forestieri(Institute of Oncology Research), Federico Jauk(Institute of Oncology Research), Ilaria Romano(University of Padua), Alessio Bruscaggin(Institute of Oncology Research)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378